Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese
详细信息 查看全文
- 作者：Da Pang (1) (2)
Yashuang Zhao (3)
Weinan Xue (1)
Ming Shan (1)
Yanbo Chen (1)
Youxue Zhang (1)
Guoqiang Zhang (1)
Feng Liu (1)
Dalin Li (1)
Yanmei Yang (2) - 关键词：Breast cancer ; Epigenetic ; Methylation ; Hereditary ; BRCA1
- 刊名：Medical Oncology
- 出版年：2012
- 出版时间：September 2012
- 年：2012
- 卷：29
- 期：3
- 页码：1561-1568
- 全文大小：373KB
- 参考文献：1. Ahmedin J, Freddie B, Melissa M, Jacques F, Elizabeth W, David F. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-0. CrossRef
2. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. / BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007;12(2):142-0. CrossRef
3. Pasche B. Recent advances in breast cancer genetics. Cancer Treat Res. 2008;141:1-0. CrossRef
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S. A strong candidate for the breast and ovarian cancer susceptibility gene / BRCA1. Science. 1994;266(5182):66-1. CrossRef
5. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC. Pregnancies, breast-feeding, and breast cancer risk in the international / BRCA1/2 carrier cohort study (IBCCS). J Natl Cancer Inst. 2006;98(8):535-4. CrossRef
6. Gorski JJ, Kennedy RD, Hosey AM, Harkin DP. The complex relationship between / BRCA1 and ERα in hereditary breast cancer. Clin Cancer Res. 2009;15(5):1514-. CrossRef
7. Xu X, Gammon MD, Zhang Y, et al. / BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2009;115(2):397-04. CrossRef
8. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-2. CrossRef
9. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control. 2009;20(9):1539-0. CrossRef
10. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-1. CrossRef
11. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased / BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis. 2000;21(9):1761-. CrossRef
12. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci. 2002;59(2):241-7. CrossRef
13. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the / BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38. CrossRef
14. Suter CM, Martin DI, Ward RL. Germline epimutation of / MLH1 in individuals with multiple cancers. Nat Genet. 2004;36(5):497-01. CrossRef
15. Suijkerbuijk KP, Fackler MJ, Sukumar S, et al. Methylation is less abundant in / BRCA1-associated compared with sporadic breast cancer. Ann Oncol. 2008;19(11):1870-. CrossRef
16. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the / BRCA1 CpG island promoter is associated with decreased / BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 1998;17(14):1807-2. CrossRef
17. Honrado E, Osorio A, Milne RL, et al. Immunohistochemical classification of non- / BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of / BRCAX families. Mod Pathol. 2007;20(12):1298-06. CrossRef
18. Ali AB, Iau PT, Sng JH. Cancer-specific methylation in the / BRCA1 promoter in sporadic breast tumours. Med Oncol. 2010. [Epub ahead of print].
19. Tapia T, Smalley SV, Kohen P, Mu?oz A, Solis LM, Corvalan A. Promoter hypermethylation of / BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008;3(3):157-3. CrossRef
20. Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, Xie Y, Deng D. / BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci. 2009;100:1663-. CrossRef
21. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. / BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179-6. CrossRef
22. Zhao Z, Han L. CpG islands: algorithms and applications in methylation studies. Biochem Biophys Res Commun. 2009;382(4):643-. CrossRef
23. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21(35):5400-3. CrossRef
24. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168-4. CrossRef
25. Zhu WG, Srinivasan K, Dai Z, Duan W, et al. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21 (Cip1) promoter. Mol Cell Biol. 2003;23(12):4056-5. CrossRef
26. Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by mCpmCpG methylation. Gene. 1997;195(1):67-1. CrossRef
27. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 1988;2(9):1136-3. CrossRef
28. Mancini DN, Rodenhiser DI, Ainsworth PJ, O’Malley FP, Singh SM, Xing W. CpG methylation within the 5-regulatory region of the / BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene. 1998;16(9):1161-. CrossRef
29. Catteau A, Joanna R. Morris. / BRCA1 methylation: a significant role in tumour development. Semin Cancer Biol. 2002;12(5):359-1. CrossRef
30. Hitchins MP, Ward RL. Erasure of / MLH1 methylation in spermatozoa- implications for epigenetic inheritance. Nat Genet. 2007;39:1289. CrossRef
31. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351-. CrossRef
32. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219-0. CrossRef
33. Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat. 2007;106(2):263-1. CrossRef
34. Abreu PA, Dellamora-Ortiz G, Le?o-Ferreira LR, et al. DNA mrthylation: a promising target for the twenty-first century. Expert Opin Ther Targets. 2008;12(8):1035-7. CrossRef
35. Chen Y, Toland AE, McLennan J, et al. Lack of germ-line promoter methylation in / BRCA1-negative families with familial breast cancer. Genet Test. 2006;10(4):281-. CrossRef
36. Yazici H, Terry MB, Cho YH, et al. Aberrant methylation of / RASSF1A in plasma DNA before breast cancer diagnosis in the breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2723-. CrossRef - 作者单位：Da Pang (1) (2)
Yashuang Zhao (3)
Weinan Xue (1)
Ming Shan (1)
Yanbo Chen (1)
Youxue Zhang (1)
Guoqiang Zhang (1)
Feng Liu (1)
Dalin Li (1)
Yanmei Yang (2)
1. Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, HaPing Road 158, Harbin, China
2. Institute of Cancer Prevention and Treatment, Harbin Medical University, BaoJian Road 6, Harbin, 150081, China
3. Epidemiology Department, Harbin Medical University, BaoJian Road 157, Harbin, China
文摘
The development of breast cancer is a multistep process associated with complex changes in host gene expression patterns including inactivation of tumor suppressor genes and activation of oncogenes. Critically, hereditary predisposition plays a significant role in cancer susceptibility. However, mutation of the BRCA1 gene is found only in the minority of hereditary breast cancer, which indicates that there might be alternative, novel mechanisms contributing to inactivation of the BRCA1 gene. Studies have shown that aberrant methylation of genomic DNA plays an important role in carcinogenesis. The aim of this study was to investigate whether DNA methylation may be an alternative mechanism for the inactivation of BRCA1 as an epigenetic modification of the genome and whether hereditary breast cancer has a different BRCA1 methylation phenotype pattern than sporadic breast cancer. The pattern of CpG island methylation within the promoter region of BRCA1 was assessed by bisulfite sequencing DNA from peripheral blood cells of 72 patients with hereditary predisposition but without BRCA1 mutations and 30 sporadic breast cancer controls. The overall methylation level in patients with hereditary predisposition was significantly lower than that in the sporadic control group. However, patients with hereditary predisposition showed a significantly higher methylation susceptibility for the sites ?18 when compared to controls. These results suggest that there might be different BRCA1 promoter methylation levels and patterns in sporadic and hereditary breast cancer in peripheral blood DNA. These findings may facilitate the early diagnosis of hereditary breast cancer.